Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04117113 · ClinicalTrials.gov registry record
Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2)
A clinical trial, sponsored by UMC Utrecht.
- Completed
- Registry status
- 238
- Enrollment target
NCT04117113: Completed study, sponsored by UMC Utrecht.
NCT04117113 is a clinical trial that has completed, run by UMC Utrecht. The registered enrollment target is 238 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04117113 has completed, sponsored by UMC Utrecht.
- COMPLETED
- Registry status
- 238 participants
- Enrollment target
Study Summary
The purpose of this study is to collect information from study participants who are hospitalized with an invasive disease caused by Extraintestinal pathogenic E. coli (ExPEC). This information will be used to support the development of a new vaccine to prevent Extraintestinal pathogenic Escherichia coli (ExPEC). E. coli bacteria are a leading cause of serious infections. Especially adults older than 60 years have a higher risk of developing such infections. To date, there is no vaccine available to prevent E. coli infections. To support the development of a vaccine, more information about E. coli infections is first needed. This information will be collected in the current study, such as: * Medical information such as medical history, diagnosis, duration of hospitalization * Treatment and outcome of the Extraintestinal pathogenic Escherichia coli (ExPEC) * Laboratory information
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2019-10-22 |
| Est. Completion | 2021-05-12 |
What the finished NCT04117113 record still lists
NCT04117113 is an observational study that tracks outcomes without assigning an intervention. The registered 238 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04117113 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04117113 about?
NCT04117113 is a clinical study titled "Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli-2 (EXPECT-2)". The purpose of this study is to collect information from study participants who are hospitalized with an invasive disease caused by Extraintestinal pathogenic E. coli (ExPEC). This information will be used to support the development of a new vaccine to prevent Extraintestinal pathogenic Escherichia ...
What is the current status of trial NCT04117113?
This trial is currently completed. The enrollment target is 238 participants. The study started on 2019-10-22. Estimated completion is 2021-05-12.
Who is sponsoring clinical trial NCT04117113?
This trial is sponsored by UMC Utrecht, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05012072 · 238 participants · NA
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
- NCT05400252 · 238 participants · NA
Whole Health in VA Mental Health: Omnis Salutis
- NCT06380517 · 238 participants · Phase 3
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
- NCT06452797 · 238 participants · NA
Prognostic Estimates Among ICU Clinicians
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI